An approach to the use of antihypertensive drugs in children and adolescents

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 4, 2001, Pages 329-350

  Wells, Thomas ^a,b   Stowe, Cindy ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Antihypertensives; Children; Hypertension; Hypertensive emergencies; Neonates; Pediatrics

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; NADOLOL; PROPRANOLOL; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CHILD; CONFERENCE PAPER; DIABETES MELLITUS; DRUG SELECTIVITY; DRUG USE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENOVASCULAR DISEASE;

EID: 0035024238     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80016-3     Document Type: Conference Paper

References (91)

1. Normal blood pressure and the evaluation of sustained blood pressure elevation in childhood: The Muscatine study
2. Validity of mass blood pressure screening in children
3. Adolescent hypertension. I. Detection and prevalence
4. Hypertension testing among high school students. I. Surveillance procedures and results
5. "Significant" diastolic hypertension in prehigh school black and white children. The children and adolescent blood pressure program
6. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program
7. White-coat hypertension in adults and children
8. "White-coat" hypertension in children
9. 24 Hour blood pressure monitoring in healthy and hypertensive children
10. Twenty-four-hour ambulatory blood pressure monitoring in young children
11. Prevalence of white coat hypertension in children with elevated casual BP
12. Ambulatory blood pressure monitoring in hypertensive adolescents
13. Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension
14. Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient
15. Ambulatory blood pressure monitoring and hypertensive target-organ damage in children
16. Hypertension and the kidney
17. Definition, prevalence, and distribution of causes of hypertension
18. Report of the Second Task Force on Blood Pressure Control in Children - 1987. National Heart, Lung, and Blood Institute, Bethesda, Maryland
19. Secular trends of blood pressure and body size in a multi-ethnic adolescent population: 1986 to 1996
20. Is there an epidemic of cardiovascular disease on the horizon?
21. Essential hypertension: A disorder of growth with origins in childhood?
22. Relations of left ventricular geometry and function to body composition in children with casual high blood pressure
23. Determinants of adolescent blood pressure: Findings from the Glasgow University student cohort
24. Management of hypertensive emergencies
25. Clinical spectrum of intrinsic renovascular hypertension in children
26. Distribution of target-organ abnormalities by race and sex in children with essential hypertension
27. Hypertension-induced cardiac damage in children and adolescents
28. Trials of antihypertensive therapies in children
29. Pharmacokinetics of enalapril in hypertensive children and infants
30. Effects of the ACE inhibitor, enalapril, in children age 6-16 years with hypertension
31. A double-blind, placebo-controlled dose escalation safety and efficacy study of Ziac in patients, ages 6-17 years, with hypertension
32. Treatment of pediatric hypertension
33. Pharmacological management of hypertension in paediatric patients: A comprehensive review of the efficacy, safety and dosage guidelines of the available agents
34. Joint National Committee VI: Individualized versus indiscriminate therapy for hypertension
35. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
36. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
37. Report of the Task Force on Blood Pressure Control in Children
38. Hypertension in children
39. Treatment of hypertension
40. National High Blood Pressure Education Program. Working group report on hypertension in diabetes
41. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
42. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study
43. Recent clinical trials: A critical appraisal
44. The World Health Organization-International Society of Hypertension blood pressure lowering treatment trialists' collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments
45. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers
46. Coronary heart disease prevention as the primary goal in contemporary trials in the treatment of hypertension
47. Doxazosin arm of the ALLHAT study discontinued: How equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
48. The risk of myocardial infarction associated with antihypertensive drug therapies
49. Issues, goals, and guidelines in selecting first-line drug therapy for hypertension
50. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
51. The emergency management of severe hypertension
52. Brain revascularisation in hypertension
53. Intravenous nicardipine in hypertensive children
54. Intravenously administered labetalol for treatment of hypertension in children
55. Modern management of hypertension
56. Hypertension in children
57. Treatment of hypertension in children
58. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises
59. Neonatal hypertension: Diagnosis and management
60. Use of short acting nifedipine in pediatric patients with hypertension
61. Use of angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension
62. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children
63. Two-year clinical follow-up of children and adolescents after percutaneous transluminal angioplasty for renovascular hypertension
64. Use of interventional radiology for hypertension due to renal artery stenosis in children
65. Midaortic syndrome and hypertension in childhood
66. Pediatric renovascular hypertension: A thirty-year experience of operative treatment
67. Pediatric renovascular hypertension
68. Drug therapy of renovascular hypertension
69. Captopril-induced reversible acute renal failure in an infant with coarctation of the aorta
70. Use of enalapril and enalaprilat in pediatric hypertension and renal disease
71. Clinical neonatal nephrology
72. The pharmacology and therapeutics of diuretics in the pediatric patient
73. Inhibition and induction of cytochrome P450 and the clinical implications
74. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
75. Pharmacologic management of childhood hypertension
76. Treatment of neonatal hypertension with enalaprilat
77. Neurologic complications of captopril treatment of neonatal hypertension
78. Renal failure in sick hypertensive premature infants receiving captopril therapy
79. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease
80. Committee on Sports Medicine and Fitness. Athletic participation by children and adolescents who have systemic hypertension
81. Alpha- and beta-adrenergic blocking drugs
82. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men
83. Contemporary management of refractory hypertension
84. Drug-induced hypertension in infancy
85. Hypertension and convulsions in children receiving cyclosporin A